Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers
Veracyte announced that more than 15 studies highlighting its Decipher portfolio will be presented at the 2026 AUA Annual Meeting. The data focuses on the clinical utility of Decipher Bladder for molecular subtyping in bladder cancer and the real-world impact of Decipher Prostate in informing treatment decisions.
Key figures
- Grid profiles
- more than 200,000
- Studies presented
- more than 15
- Decipher bladder genes
- 219
- Decipher prostate genes
- 22
- Prostate validation patients
- more than 100,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.